Latest Pharma Insights
China’s Mid-Cap Companies Thriving On Big Pharma Deals
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Scrip - July 15, 2025
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Scrip - July 15, 2025
Vision Healthcare Strikes Deals To Expand European Offering
Belgium-based Vision Healthcare has acquired Svenskt Kosttillskott in Sweden and New Care Supplements in the Netherlands.
HBW Insight - July 15, 2025
Belgium-based Vision Healthcare has acquired Svenskt Kosttillskott in Sweden and New Care Supplements in the Netherlands.
HBW Insight - July 15, 2025
Making The UK A Leading Biosimilar Launch Destination – Realistic Or Optimistic?
Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.
Generics Bulletin - July 15, 2025
Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.
Generics Bulletin - July 15, 2025
In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy
Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.
Scrip - July 15, 2025
Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.
Scrip - July 15, 2025
Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.
In Vivo - July 15, 2025
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.
In Vivo - July 15, 2025
Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
Generics Bulletin - July 15, 2025
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
Generics Bulletin - July 15, 2025
Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever
Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.
Scrip - July 15, 2025
Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.
Scrip - July 15, 2025
Wockhardt Pivots To Biosimilar Insulins Focus As It Confirms US Generics Exit
Wockhardt is exiting the US generics market through voluntary liquidation of its loss-making US subsidiaries to double down on innovation and focus on antibiotics and biosimilar insulins.
Generics Bulletin - July 15, 2025
Wockhardt is exiting the US generics market through voluntary liquidation of its loss-making US subsidiaries to double down on innovation and focus on antibiotics and biosimilar insulins.
Generics Bulletin - July 15, 2025
Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
Scrip - July 15, 2025
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
Scrip - July 15, 2025
Kenvue Makes CEO Change Months After Critical Activist Investor Made Proxy Play For Board Seat
Thibaut Mongon is out as Kenvue CEO, a post he’s held since J&J spun it out in July 2023, after the firm’s results came under increased investor scrutiny over the past year. The board appointed as interim CEO Kirk Perry, a board member since December who most recently headed technology, data and pre
HBW Insight - July 15, 2025
Thibaut Mongon is out as Kenvue CEO, a post he’s held since J&J spun it out in July 2023, after the firm’s results came under increased investor scrutiny over the past year. The board appointed as interim CEO Kirk Perry, a board member since December who most recently headed technology, data and pre
HBW Insight - July 15, 2025
China’s Mid-Cap Companies Thriving On Big Pharma Deals
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Scrip - July 15, 2025
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Scrip - July 15, 2025
In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy
Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.
Scrip - July 15, 2025
Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.
Scrip - July 15, 2025
Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever
Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.
Scrip - July 15, 2025
Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.
Scrip - July 15, 2025
Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
Scrip - July 15, 2025
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
Scrip - July 15, 2025
Warning Letters – June 2025
The US FDA posted eight device-related warning letters in June, touching on industry sectors from urinalysis test strips to ophthalmic devices.
Medtech Insight - July 14, 2025
The US FDA posted eight device-related warning letters in June, touching on industry sectors from urinalysis test strips to ophthalmic devices.
Medtech Insight - July 14, 2025
Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs
Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.
Medtech Insight - July 14, 2025
Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.
Medtech Insight - July 14, 2025
European MedTech Keeps Calm Despite US Threats Of 30% Tariffs
MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.
Medtech Insight - July 14, 2025
MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.
Medtech Insight - July 14, 2025
Medtech Will Benefit From Boost To EU’s Quantum Technology Initiative
The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”
Medtech Insight - July 14, 2025
The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”
Medtech Insight - July 14, 2025
Vision Healthcare Strikes Deals To Expand European Offering
Belgium-based Vision Healthcare has acquired Svenskt Kosttillskott in Sweden and New Care Supplements in the Netherlands.
HBW Insight - July 15, 2025
Belgium-based Vision Healthcare has acquired Svenskt Kosttillskott in Sweden and New Care Supplements in the Netherlands.
HBW Insight - July 15, 2025
Kenvue Makes CEO Change Months After Critical Activist Investor Made Proxy Play For Board Seat
Thibaut Mongon is out as Kenvue CEO, a post he’s held since J&J spun it out in July 2023, after the firm’s results came under increased investor scrutiny over the past year. The board appointed as interim CEO Kirk Perry, a board member since December who most recently headed technology, data and pre
HBW Insight - July 15, 2025
Thibaut Mongon is out as Kenvue CEO, a post he’s held since J&J spun it out in July 2023, after the firm’s results came under increased investor scrutiny over the past year. The board appointed as interim CEO Kirk Perry, a board member since December who most recently headed technology, data and pre
HBW Insight - July 15, 2025
Making The UK A Leading Biosimilar Launch Destination – Realistic Or Optimistic?
Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.
Generics Bulletin - July 15, 2025
Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.
Generics Bulletin - July 15, 2025
Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
Generics Bulletin - July 15, 2025
As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.
Generics Bulletin - July 15, 2025
Wockhardt Pivots To Biosimilar Insulins Focus As It Confirms US Generics Exit
Wockhardt is exiting the US generics market through voluntary liquidation of its loss-making US subsidiaries to double down on innovation and focus on antibiotics and biosimilar insulins.
Generics Bulletin - July 15, 2025
Wockhardt is exiting the US generics market through voluntary liquidation of its loss-making US subsidiaries to double down on innovation and focus on antibiotics and biosimilar insulins.
Generics Bulletin - July 15, 2025
Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.
In Vivo - July 15, 2025
Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.
In Vivo - July 15, 2025